Lonza Group Ag (LZAGY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

Swiss Contract Service Provider Lonza Exits Capsules Business To Focus On Drug Development Lonza unveils its "One Lonza" strategy, highlighting a new structure to streamline operations ...

SWX:LONN Earnings and Revenue History April 11th 2025 How Do Unusual Items Influence Profit? To properly understand Lonza Group's profit results, we need to consider the CHF284m e ...

Barclays analyst Charles Pitman lowered the firm’s price target on Lonza (LZAGY) to CHF 670 from CHF 710 and keeps an Overweight rating on the ...

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America ...

In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on Lonza Group Ltd (LONN – Research Report), with a price ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Lonza is a potential beneficiary given the ample ... This provides earnings visibility for the company. We anticipate the group to increase sales by 10% in 2025 to CHF 8.5 billion, and we also ...